SecBot SecBot
SECBOTREPLAY Home › Report › RVMD

RVMD · Revolution Medicines announced that Phase 1/2 data for daraxonrasib in…

Revolution Medicines, Inc. · PRESS-RELEASE filed May 6, 2026 at 18:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed May 6, 2026 at 18:00 ET

Revolution Medicines announced that Phase 1/2 data for daraxonrasib in RAS-mutant pancreatic cancer were published in NEJM, complementing recently reported positive Phase 3 topline results showing an unprecedented overall survival benefit. The drug holds FDA Breakthrough Therapy and Orphan Drug Designations, reinforcing its potential as a new standard of care for a deadly cancer with limited treatment options.

  • NEJM published Phase 1/2 data for daraxonrasib in metastatic RAS-mutant PDAC.
  • Company previously announced positive Phase 3 RASolute 302 topline results with unprecedented overall survival benefit vs. standard chemotherapy.
  • Daraxonrasib has FDA Breakthrough Therapy and Orphan Drug Designations for PDAC with G12 mutations.
  • Daraxonrasib is a RAS(ON) multi-selective inhibitor targeting diverse RAS mutations.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access